Blood Sparing Protocol for Kidney Cancer
(RESTRICT Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the Blood Sparing Protocol treatment for kidney cancer?
The research suggests that avoiding blood transfusions during kidney cancer surgery may improve outcomes, as intraoperative blood transfusions are linked to higher risks of cancer recurrence and mortality. This implies that a blood-sparing approach could potentially be beneficial in reducing these risks.12345
Is the Blood Sparing Protocol generally safe for humans?
The studies reviewed focus on blood loss and transfusion during kidney cancer surgeries, but they do not directly address the safety of the Blood Sparing Protocol itself. However, one study found that blood transfusions did not negatively impact long-term survival after kidney surgery, suggesting that managing blood loss during such procedures is generally safe.16789
How does the Blood Sparing Protocol treatment for kidney cancer differ from other treatments?
The Blood Sparing Protocol for kidney cancer is unique because it focuses on minimizing the need for blood transfusions during surgery, using techniques like preoperative autologous blood donation and intraoperative cell salvage with leukocyte depletion filters. This approach aims to reduce complications associated with blood transfusions, which can impact recovery and survival rates.13101112
What is the purpose of this trial?
The Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer Trial (RESTRICT).The primary objective is to reduce the number of units of allogenic blood transfusion in locally advanced kidney cancer (≥ cT2). Secondary objectives include reduction in perioperative complications, assessment of recurrence free-survival and improving overall survival.
Research Team
Kelvin Moses
Principal Investigator
Associate Professor
Eligibility Criteria
This trial is for adults with advanced kidney cancer (≥ cT2), who may also have some spread to lymph nodes or distant sites but are still considered candidates for surgery. They must have a heart ejection fraction of at least 45%, adequate blood counts, liver function within certain limits, and agree to follow the study rules.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo radical nephrectomy with or without blood-sparing techniques
Follow-up
Participants are monitored for safety, complications, and effectiveness after surgery
Long-term follow-up
Assessment of overall survival and kidney cancer recurrence
Treatment Details
Interventions
- Blood Sparing Protocol
- Standard Blood Replacement
Find a Clinic Near You
Who Is Running the Clinical Trial?
Vanderbilt University Medical Center
Lead Sponsor